ATE185697T1 - Androgentherapie am auge beim sjögrensyndrom - Google Patents

Androgentherapie am auge beim sjögrensyndrom

Info

Publication number
ATE185697T1
ATE185697T1 AT93910732T AT93910732T ATE185697T1 AT E185697 T1 ATE185697 T1 AT E185697T1 AT 93910732 T AT93910732 T AT 93910732T AT 93910732 T AT93910732 T AT 93910732T AT E185697 T1 ATE185697 T1 AT E185697T1
Authority
AT
Austria
Prior art keywords
eye
syndrome
sjögren
androgen therapy
androgen
Prior art date
Application number
AT93910732T
Other languages
English (en)
Inventor
David A Sullivan
Original Assignee
Schepens Eye Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schepens Eye Res Inst filed Critical Schepens Eye Res Inst
Application granted granted Critical
Publication of ATE185697T1 publication Critical patent/ATE185697T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Eye Examination Apparatus (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT93910732T 1992-04-21 1993-04-21 Androgentherapie am auge beim sjögrensyndrom ATE185697T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87165792A 1992-04-21 1992-04-21

Publications (1)

Publication Number Publication Date
ATE185697T1 true ATE185697T1 (de) 1999-11-15

Family

ID=25357867

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93910732T ATE185697T1 (de) 1992-04-21 1993-04-21 Androgentherapie am auge beim sjögrensyndrom

Country Status (11)

Country Link
US (1) US5620921C1 (de)
EP (1) EP0643581B1 (de)
JP (1) JPH07508716A (de)
AT (1) ATE185697T1 (de)
AU (1) AU674681B2 (de)
CA (1) CA2133966C (de)
DE (1) DE69326836T2 (de)
DK (1) DK0643581T3 (de)
ES (1) ES2139005T3 (de)
GR (1) GR3032326T3 (de)
WO (1) WO1993020823A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5688765A (en) * 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
CA2157934A1 (en) * 1993-03-12 1994-09-15 Timothy R. Willis Eye care products containing a pheromone additive and method of using the same
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US6462080B1 (en) 1998-12-24 2002-10-08 Alcon Manufacturing, Ltd. Prostaglandin E receptor agonists for treatment of dry eye
WO2000038663A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
PL356127A1 (en) 1999-11-09 2004-06-14 Alcon Inc. Omega chain modified 15-hydroxyeicosatetraenoic acid derivatives and methods of their use for the treatment of dry eye
AU1226001A (en) 1999-11-09 2001-06-06 Alcon Universal Limited Phospholipids of hydroxyeicosatetraenoic acid-like derivatives
ATE257143T1 (de) 1999-11-09 2004-01-15 Alcon Inc 15-hydroxyeicosatetraensäure verwandte verbindungen und anwendungsverfahren
US6552084B2 (en) 1999-11-09 2003-04-22 Alcon Universal Ltd. Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
US6458854B2 (en) 1999-11-09 2002-10-01 Alcon Universal Ltd. Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
JP2003513951A (ja) 1999-11-09 2003-04-15 アルコン，インコーポレイテッド ヒドロキシエイコサテトラエン酸誘導体を含有する組成物およびドライアイ障害の処置における使用方法
WO2001034550A2 (en) 1999-11-09 2001-05-17 Alcon Universal Ltd. 15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
ATE292464T1 (de) 1999-11-09 2005-04-15 Alcon Inc Heteroatomunterbrochene analoge von15- hydroxyeicosatetraensäure und verfahren zu deren verwendung
US6645978B1 (en) 1999-11-09 2003-11-11 Alcon, Inc. Lipoxin A4 and its analogs for the treatment of dry eye
US6803385B2 (en) 1999-11-09 2004-10-12 Alcon, Inc. Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
EP1228030B1 (de) 1999-11-09 2005-06-01 Alcon Inc. Benzenoidderivate von 15-hydroxyeicosatetraensäure und verfahren zur verwendung zur behandlung des trockenen auges
US6255343B1 (en) 1999-11-09 2001-07-03 Alcon Universal Ltd. 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
US6429227B1 (en) 1999-11-09 2002-08-06 Alcon Universal Ltd. Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders
CA2386333A1 (en) 1999-11-09 2001-05-17 Alcon, Inc. 3-heteroatom substituted and two carbon homologs 15-hete and methods of use
WO2001046134A1 (en) 1999-12-22 2001-06-28 Alcon Universal Ltd. 6-KETO PROSTAGLANDIN F1α AND ANALOGS FOR TREATING DRY EYE
DK2153819T3 (da) 2000-07-14 2012-12-03 Allergan Inc Anvendelse af en opløselighedsforbedrende bestanddel i en vandig sammensætning omfattende brimonidintartrat
DK1330246T3 (da) 2000-10-23 2005-08-08 Alcon Inc Anvendelse af hydroxyicosatetraensyrederivater ved intraokulær kirurgi
PT1393277E (pt) 2001-05-21 2006-09-29 Alcon Inc Utilizacao de inibidores de nf-kb para tratar disturbios de olho seco
US7112588B2 (en) * 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
DE60218153T2 (de) 2001-05-21 2007-06-28 Alcon Inc. Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
PL367097A1 (en) * 2001-05-21 2005-02-21 Alcon, Inc. Method of treating dry eye disorders
US6645994B1 (en) 2001-06-01 2003-11-11 Alcon, Inc. Method of treating dry eye disorders
WO2003030894A1 (en) * 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye
KR20050030884A (ko) * 2001-10-11 2005-03-31 알콘, 인코퍼레이티드 항염증성 스테로이드 및 ｍｕｃ-1 분비촉진제 배합에 의한안구 건조증 치료 방법
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US20040248794A1 (en) * 2002-12-20 2004-12-09 Yanni John M. Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells
TWI335819B (en) * 2002-12-24 2011-01-11 Alcon Inc Use of oculosurface selective glucocorticoid in the treatment of dry eye
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
FR2877574A1 (fr) * 2004-11-08 2006-05-12 Marie Claude Benattar Utilisation d'acide hyaluronique, eventuellement en association avec au moins un androgene pour le traitement de troubles sexuels ou urinaires feminins par amplification du point g et compositions.
CA2644652A1 (en) * 2005-03-02 2006-09-08 Nascent Pharmaceuticals, Inc. Combinaion therapy for topical application in the treatment of dry eye syndrome
CN101282646B (zh) * 2005-07-12 2013-03-27 Dmi生物科学公司 治疗疾病的方法和产品
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
SI2915529T1 (sl) * 2008-05-07 2017-09-29 The Regents Of The University Of California Terapevtska regeneracija in obogatitev lubrikacije okularne površine
AU2010264525B2 (en) * 2009-06-22 2015-04-02 Ampio Pharmaceuticals, Inc. Methods and products for treatment of diseases
PT2554174E (pt) * 2009-06-22 2015-12-15 Ampio Pharmaceuticals Inc Método para o tratamento de doenças
EP3388066B1 (de) 2011-01-26 2020-11-04 Allergan, Inc. Androgenzusammensetzung zur behandlung eines augenleidens
EA201500752A1 (ru) 2012-12-19 2016-05-31 Ампио Фармасьютикалс, Инк. Способ лечения заболеваний
US20140274985A1 (en) * 2013-03-15 2014-09-18 Raman Malhotra Systemic administration of androgen in treating dry eye syndrome
US20150141328A1 (en) * 2013-11-18 2015-05-21 The Schepens Eye Research Institute Stimulation of human meibomian gland function
BR112017021044A2 (pt) * 2015-04-03 2018-07-24 Santen Pharmaceutical Co., Ltd. agente terapêutico para o olho seco compreendendo nandrolona ou éster da mesma ou metenolona ou éster da mesma como um ingrediente ativo

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
US4478818A (en) * 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4581226A (en) * 1983-04-07 1986-04-08 Dillon Richard S Method of treating sensitive animal tissue with a specially processed seawater solution
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
SE8305864D0 (sv) * 1983-10-25 1983-10-25 L E Medical Ogondroppar
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4812448A (en) * 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4863912A (en) * 1986-05-19 1989-09-05 New York Medical College Use of tetrahydrocortisol in glaucoma therapy
US4861763A (en) * 1986-09-17 1989-08-29 Research Triangle Institute 17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use
US4774236A (en) * 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US4866049A (en) * 1987-08-10 1989-09-12 Spectra Pharmaceutical Services, Inc. Ophthalmic compositionn and method of using same
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US4951683A (en) * 1989-01-19 1990-08-28 Davis Jeffrey P Device for detecting keratoconjunctivitis sicca

Also Published As

Publication number Publication date
ES2139005T3 (es) 2000-02-01
US5620921C1 (en) 2001-01-09
AU4112193A (en) 1993-11-18
AU674681B2 (en) 1997-01-09
EP0643581A1 (de) 1995-03-22
JPH07508716A (ja) 1995-09-28
CA2133966C (en) 1997-09-09
CA2133966A1 (en) 1993-10-28
US5620921A (en) 1997-04-15
EP0643581A4 (de) 1995-01-11
DE69326836D1 (de) 1999-11-25
EP0643581B1 (de) 1999-10-20
DK0643581T3 (da) 2000-04-25
DE69326836T2 (de) 2000-02-24
GR3032326T3 (en) 2000-04-27
WO1993020823A1 (en) 1993-10-28

Similar Documents

Publication Publication Date Title
ATE185697T1 (de) Androgentherapie am auge beim sjögrensyndrom
EP0233758A3 (de) Gerät zum Auftragen von Creme und Flüssigkeit, zum Rollen und zum Massieren des Körpers
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
NO951592D0 (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
EP0142426A3 (de) Ophthalmische Zusammensetzung enthaltend Norfloxacin und verwandte Antibiotika
DE69214938D1 (de) Mittel zur topischen verabreichung von arzneiwirkstoffen
AU7085996A (en) Therapeutic preparation for the transdermal application of active substances through the skin
ES2179820T3 (es) Dispositivo de administracion transdermica de farmacos subsaturados con flujo de farmaco incrementado.
ES550011A0 (es) Un metodo de administracion de una cantidad terapeuticamenteefectiva de timolol
IE791235L (en) Acyl-derivatives of carnitine.
IE40860L (en) N- heterocyclylalkylbenzamides
DK71387D0 (da) Terapeutisk middel til behandling af psoriasis
IT1177863B (it) Una miscela gangliosidica come agente terapeutico capare di eliminare il dolore nele neuropatie periferiche
EP0363469A4 (en) Lacrimal secretion stimulant (lss)
ATE151977T1 (de) Therapeutisch wirksame, örtliche anwendung von st1435
DK0579488T3 (da) Præparat til behandling af mastitis og matritis
TW259710B (de)
IT1148189B (it) 1-(p-2-isopropossietossimetil-fenossi)-3-isopropilammino-propan-2-olo e suoi sali per l'abbassamento della pressione endooculare e preparati oftalmici che li contengono
ATE180667T1 (de) Verwendung grenzwertig wirksamer arzneiformen mit betablockern
GB1523001A (en) Foot massage appliance
汪承柏 et al. THE JAUNDICE-SUPPRESSING EFFECT OF BLOOD-COOLING, CIRCULATION-INVIGORATING, VISCERA-DREDGING AND CHOLAGOGIC CHINESE HERBS IN THE TREATMENT OF HEPATITIS
ES8602799A1 (es) Un procedimiento para preparar 6-metilsulfoxido-espiro-(croman-4,4'-imidazolidin)-2',5'-diona
LV10197A (lv) Terapeitisks preparats
葛通远 et al. AN APPROACH TO THE MECHANISMS OF LASER ACUPUNCTURE IN TREATMENT OF EXOPHTHALMIC HYPERTHYROIDISM
WO1997004790A3 (de) Arzneimittel zur behandlung von ulcera welches magnesiumionen als wirksubstanz umfasst